Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus Price Target from Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received a consensus recommendation of “Hold” from the five analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $95.00.

A number of research firms have issued reports on ATOS. Ascendiant Capital Markets boosted their price target on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st.

Atossa Genetics Stock Up 3.9%

NASDAQ:ATOS opened at $5.33 on Friday. Atossa Genetics has a 52-week low of $3.76 and a 52-week high of $19.35. The stock has a fifty day simple moving average of $6.11 and a 200-day simple moving average of $10.16. The company has a market capitalization of $45.89 million, a PE ratio of -1.48 and a beta of 1.42.

Hedge Funds Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATOS. &PARTNERS purchased a new stake in shares of Atossa Genetics during the 4th quarter worth about $25,000. Hudson Bay Capital Management LP bought a new position in Atossa Genetics during the second quarter valued at about $26,000. Gallagher Capital Advisors LLC bought a new stake in Atossa Genetics in the 3rd quarter valued at $27,000. JPMorgan Chase & Co. raised its position in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd bought a new position in shares of Atossa Genetics during the 2nd quarter worth approximately $49,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.